Acadia Pharmaceuticals Share Price Today
(NASDAQ: ACAD)

Name: Acadia Pharmaceuticals Share Price Today (NASDAQ: ACAD) - Acadia Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Acadia Pharmaceuticals share price is $18.73 & ₹1,631.29 as on 5 Feb 2025, 2.30 'hrs' IST

$18.73

▲

0.22

(1.19%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Acadia Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Acadia Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Acadia Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Acadia Pharmaceuticals share price movements

Today's Low: $18.47
Today's High: $18.83
$18.73
1.39%
Downside
Day's Volatility :1.92%
Upside
0.54%
52 Weeks Low: $14.15
52 Weeks High: $26.78
$18.73
24.45%
Downside
52 Weeks Volatility :47.16%
Upside
30.06%

Acadia Pharmaceuticals (ACAD) Returns

Period	Acadia Pharmaceuticals Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	17.23%	0.5%	0.0%
6 Months	22.02%	-2.3%	0.0%
1 Year	-28.09%	3.8%	0.0%
3 Years	-26.87%	11.4%	-11.7%

Acadia Pharmaceuticals (ACAD) Key Statistics

in dollars & INR

Previous Close	$18.51
Open	$18.52
Today's High	$18.831
Today's Low	$18.47
Market Capitalization	$3.1B
Today's Volume	$1.5M
52 Week High	$26.78
52 Week Low	$14.15
Revenue TTM	$929.2M
EBITDA	$124.5M
Earnings Per Share (EPS)	$0.78
PE Ratio	23.92
Profit Margin	13.83%
Quarterly Earnings Growth YOY	28.35%
Return On Equity TTM	27.36%

How to invest in Acadia Pharmaceuticals Stock (ACAD) from India?

It is very easy for Indian residents to invest directly in Acadia Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Acadia Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Acadia Pharmaceuticals or ACAD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Acadia Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Acadia Pharmaceuticals shares which would translate to 0.047 fractional shares of Acadia Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Acadia Pharmaceuticals, in just a few clicks!

Returns in Acadia Pharmaceuticals (ACAD) for Indian investors in Rupees

The Acadia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Acadia Pharmaceuticals investment value today

Current value as on today

₹77,631

Returns

₹22,369

(-22.37%)

Returns from Acadia Pharmaceuticals Stock

₹27,234 (-27.23%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Acadia Pharmaceuticals (ACAD)

-32%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Acadia Pharmaceuticals Stock from India on INDmoney has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Acadia Pharmaceuticals

Baker Bros Advisors LP
25.77%
Vanguard Group Inc
8.32%
RTW INVESTMENTS, LLC
8.24%
BlackRock Inc
7.69%
State Street Corp
3.59%
D. E. Shaw & Co LP
2.11%

Analyst Recommendation on Acadia Pharmaceuticals

Buy

73%Buy

23%Hold

3%Sell

Based on 26 Wall street analysts offering stock ratings for Acadia Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 26 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Acadia Pharmaceuticals Stock (ACAD)

What analysts predicted

Upside of 33.19%

Target:

$24.95

Current:

$18.73

Insights on Acadia Pharmaceuticals Stock (Ticker Symbol: ACAD)

Price Movement
In the last 3 months, ACAD stock has moved up by 26.6%
Increasing Revenue
Revenue is up for the last 3 quarters, 205.83M → 250.40M (in $), with an average increase of 9.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 33.38M → 32.76M (in $), with an average decrease of 1.9% per quarter
ACAD vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 58.6% return, outperforming this stock by 85.4%
ACAD vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 88.8% return, outperforming this stock by 110.4%
Price to Sales
ForACAD every $1 of sales, investors are willing to pay $3.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.6 for every $1 of sales.

ACAD Acadia Pharmaceuticals Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$223.8M	↑ 79.19%
Net Income	$-245.2M	↓ 15.28%
Net Profit Margin	-109.56%	↑ 122.15%

	FY19	Y/Y Change
Revenue	$339.1M	↑ 51.5%
Net Income	$-235.3M	↓ 4.05%
Net Profit Margin	-69.38%	↑ 40.18%

	FY20	Y/Y Change
Revenue	$441.8M	↑ 30.28%
Net Income	$-281.6M	↑ 19.69%
Net Profit Margin	-63.74%	↑ 5.64%

	FY21	Y/Y Change
Revenue	$484.1M	↑ 9.6%
Net Income	$-167.9M	↓ 40.38%
Net Profit Margin	-34.67%	↑ 29.07%

	FY22	Y/Y Change
Revenue	$517.2M	↑ 6.83%
Net Income	$-216.0M	↑ 28.66%
Net Profit Margin	-41.76%	↓ 7.09%

	FY23	Y/Y Change
Revenue	$726.4M	↑ 40.45%
Net Income	$-61.3M	↓ 71.62%
Net Profit Margin	-8.44%	↑ 33.32%

	Q2 FY23	Q/Q Change
Revenue	$165.2M	↑ 39.48%
Net Income	$1.1M	↓ 102.59%
Net Profit Margin	0.67%	↑ 36.99%

	Q3 FY23	Q/Q Change
Revenue	$211.7M	↑ 28.12%
Net Income	$-65.2M	↓ 5950.63%
Net Profit Margin	-30.79%	↓ 31.46%

	Q4 FY23	Q/Q Change
Revenue	$231.0M	↑ 9.14%
Net Income	$45.8M	↓ 170.27%
Net Profit Margin	19.82%	↑ 50.61%

	Q1 FY24	Q/Q Change
Revenue	$205.8M	↓ 10.91%
Net Income	$16.6M	↓ 63.85%
Net Profit Margin	8.04%	↓ 11.78%

	Q2 FY24	Q/Q Change
Revenue	$242.0M	↑ 17.55%
Net Income	$33.4M	↑ 101.69%
Net Profit Margin	13.8%	↑ 5.76%

	Q3 FY24	Q/Q Change
Revenue	$250.4M	↑ 3.49%
Net Income	$32.8M	↓ 1.87%
Net Profit Margin	13.09%	↓ 0.71%

	FY18	Y/Y Change
Profit	$205.5M	↑ 83.72%

	FY19	Y/Y Change
Profit	$319.5M	↑ 55.48%

	FY20	Y/Y Change
Profit	$421.2M	↑ 31.84%

	FY21	Y/Y Change
Profit	$465.0M	↑ 10.4%

	FY22	Y/Y Change
Profit	$507.1M	↑ 9.05%

	FY23	Y/Y Change
Profit	$680.7M	↑ 34.24%

	Q2 FY23	Q/Q Change
Profit	$157.8M	↑ 35.09%

	Q3 FY23	Q/Q Change
Profit	$197.1M	↑ 24.91%

	Q4 FY23	Q/Q Change
Profit	$213.2M	↑ 8.16%

	Q1 FY24	Q/Q Change
Profit	$182.9M	↓ 14.2%

	Q2 FY24	Q/Q Change
Profit	$223.7M	↑ 22.34%

	Q3 FY24	Q/Q Change
Profit	$231.5M	↑ 3.49%

	FY18	Y/Y Change
Operating Cash Flow	$-167.5M	↓ 23.13%
Investing Cash Flow	$-71.5M	↓ 177.31%
Financing Cash Flow	$306.6M	↑ 883.22%

	FY19	Y/Y Change
Operating Cash Flow	$-151.1M	↓ 9.76%
Investing Cash Flow	$-165.8M	↑ 131.97%
Financing Cash Flow	$371.8M	↑ 21.26%

	FY20	Y/Y Change
Operating Cash Flow	$-136.2M	↓ 9.9%
Investing Cash Flow	$192.5M	↓ 216.08%
Financing Cash Flow	$81.0M	↓ 78.22%

	FY21	Y/Y Change
Operating Cash Flow	$-125.7M	↓ 7.72%
Investing Cash Flow	$-71.1M	↓ 136.93%
Financing Cash Flow	$18.2M	↓ 77.58%

	FY22	Y/Y Change
Operating Cash Flow	$-114.0M	↓ 9.25%
Investing Cash Flow	$73.2M	↓ 203.01%
Financing Cash Flow	$8.2M	↓ 54.86%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$8.2M	↓ 145.73%
Investing Cash Flow	$-194.3M	↓ 200.92%
Financing Cash Flow	$5.5M	↑ 273.67%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-59.0M	↓ 818.88%
Investing Cash Flow	$34.1M	↓ 117.56%
Financing Cash Flow	$12.8M	↑ 132.77%

Acadia Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Acadia Pharmaceuticals (ACAD) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Acadia Pharmaceuticals Inc.	6.01%	22.02%	-28.09%	-26.87%	-55.58%
Biontech Se	-0.32%	51.19%	24.81%	-30.66%	288.02%
Regeneron Pharmaceuticals, Inc.	-6.9%	-37.55%	-28.89%	7.15%	74.63%
Vertex Pharmaceuticals Incorporated	16.87%	0.96%	13.03%	93.36%	95.94%
Alnylam Pharmaceuticals, Inc.	17.76%	5.53%	59.46%	84.7%	118.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Acadia Pharmaceuticals Inc.	23.92	23.92	-0.42	0.7	0.27	0.09	NA	3.47
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.64	16.64	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Acadia Pharmaceuticals Inc.	Buy	$3.1B	-55.58%	23.92	13.83%
Biontech Se	Buy	$29.7B	288.02%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.0B	74.63%	16.64	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$118.9B	95.94%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.0B	118.8%	NA	-15.86%

About Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Organization	Acadia Pharmaceuticals
Employees	620
CEO	Mr. Mark C. Schneyer
Industry	Health Technology

Management People of Acadia Pharmaceuticals

Name	Title
Mr. Mark C. Schneyer	Chief Financial Officer
Mr. Stephen R. Davis J.D.	Consultant
Ms. Catherine E. Owen Adams	CEO & Director
Mr. James K. Kihara	VP, Chief Accounting Officer & Corporate Controller
Dr. Elizabeth H.Z. Thompson Ph.D.	Head of Research & Development
Mr. Benir Ruano	Senior Vice President of Technical Development, Operations & Quality
Mr. Albert S. Kildani	Senior Vice President of Investor Relations & Corporate Communications
Ms. Jennifer J. Rhodes J.D.	Chief Legal Officer & Secretary
Mr. Rob Ackles	Chief People Officer
Mr. Bob Mischler	Senior Vice President of New Product Planning & Strategy

Important FAQs about investing in ACAD Stock from India :

What is Acadia Pharmaceuticals share price today?

Acadia Pharmaceuticals share price today stands at $18.73, Open: $18.52 ; Previous Close: $18.51 ; High: $18.83 ; Low: $18.47 ; 52 Week High: $26.78 ; 52 Week Low: $14.15.

The stock opens at $18.52, after a previous close of $18.51. The stock reached a daily high of $18.83 and a low of $18.47, with a 52-week high of $26.78 and a 52-week low of $14.15.

Can Indians buy Acadia Pharmaceuticals shares?

Yes, Indians can invest in the Acadia Pharmaceuticals (ACAD) from India.

With INDmoney, you can buy Acadia Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Acadia Pharmaceuticals at zero transaction cost.

How can I buy Acadia Pharmaceuticals shares from India?

It is very easy to buy Acadia Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Acadia Pharmaceuticals (ACAD) be purchased?

Yes, you can buy fractional shares of Acadia Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Acadia Pharmaceuticals stocks?

To start investing in Acadia Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.